ReviewMarine drugs2016
Fucoidan as a Potential Therapeutic for Major Blinding Diseases--A Hypothesis.
Review in Marine drugs, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 47 citations in OpenAlex.
- Influence of a Very High-Molecular Weight Fucoidan fromMarine drugs · 2025Article
- Undaria pinnatifida fucoidan extract inhibits activation of the NF-κB signaling pathway by herpes simplex virus type 1 and prevents amyloid-β peptide synthesis in retinal pigment epithelium cells.Archives of virology · 2025Article
- Effects of Fucoidans on Activated Retinal Microglia.International journal of molecular sciences · 2024Article
- Alleviative Effect of Iodine Pretreatment on the Stress ofInternational journal of molecular sciences · 2023Article
- Comparison of Fucoidans fromInternational journal of molecular sciences · 2023Article
- Anti-inflammatory properties of antiangiogenic fucoidan in retinal pigment epithelium cells.Heliyon · 2023Article
- Interaction of High-Molecular Weight Fucoidan fromInternational journal of molecular sciences · 2023Article
- Lurbinectedin improves macular edema in a case of central retinal vein occlusion.American journal of ophthalmology case reports · 2022Article
- The Potential of Dietary Bioactive Compounds against SARS-CoV-2 and COVID-19-Induced Endothelial Dysfunction.Molecules (Basel, Switzerland) · 2022Review
- Evaluation of the Effects of Fucoidans fromMarine drugs · 2021Article
- Evaluation of a Brown Seaweed Extract fromMarine drugs · 2020Article
- Fucoidans as Potential Therapeutics for Age-Related Macular Degeneration-Current Evidence from In Vitro Research.International journal of molecular sciences · 2020Review
- Effects of a Newly Developed Enzyme-Assisted Extraction Method on the Biological Activities of Fucoidans in Ocular Cells.Marine drugs · 2020Article
- Fucoidans: Downstream Processes and Recent Applications.Marine drugs · 2020Review
- Article
- Transcriptome sequencing of Saccharina japonica sporophytes during whole developmental periods reveals regulatory networks underlying alginate and mannitol biosynthesis.BMC genomics · 2019Article
- Therapies from Fucoidan: New Developments.Marine drugs · 2019Review
- Effects of Sulfated Fucans fromMarine drugs · 2019Article
- Effects of CrudeMarine drugs · 2019Article
- Effects of Fucoidans from Five Different Brown Algae on Oxidative Stress and VEGF Interference in Ocular Cells.Marine drugs · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fucoidan is a heterogeneous group of sulfated polysaccharide with a high content of l-fucose, which can be extracted from brown algae and marine invertebrates. It has many beneficial biological activities that make fucoidan an interesting candidate for therapeutic application in a variety of diseases. Age-related macular degeneration and diabetic retinopathy are major causes for vision loss and blindness in the industrialized countries and increasingly in the developing world. Some of the characteristics found in certain fucoidans, such as its anti-oxidant activity, complement inhibition or interaction with the Vascular Endothelial Growth factor, which would be of high interest for a potential application of fucoidan in age-related macular degeneration or diabetic retinopathy. However, the possible usage of fucoidan in ophthalmological diseases has received little attention so far. In this review, biological activities of fucoidan that could be of interest regarding these diseases will be discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.